Patents by Inventor Daniel Fleischanderl

Daniel Fleischanderl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230017907
    Abstract: The present invention relates to a method for continuous recovering of a protein from a fluid, comprising precipitating the protein in the fluid and separating the precipitated protein from the fluid. The invention also provides an inclined plate settler that can be used for such continuous protein recovering.
    Type: Application
    Filed: December 10, 2020
    Publication date: January 19, 2023
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Daniel FLEISCHANDERL, Christoph DATTENBOECK, Katerina PETRUSHEVSKA-SEEBACH, Thomas GATTERNIG, Martin PURTSCHER, Alois JUNGBAUER, Hannah ENGELMAIER, Nikolaus HAMMERSCHMIDT
  • Patent number: 10745672
    Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: August 18, 2020
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl
  • Publication number: 20190153400
    Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.
    Type: Application
    Filed: January 18, 2019
    Publication date: May 23, 2019
    Inventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl
  • Patent number: 10221400
    Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: March 5, 2019
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl
  • Patent number: 10100099
    Abstract: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: October 16, 2018
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl, Gregor Bramberger
  • Publication number: 20180051261
    Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.
    Type: Application
    Filed: April 12, 2017
    Publication date: February 22, 2018
    Inventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl
  • Publication number: 20180044405
    Abstract: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.
    Type: Application
    Filed: May 9, 2017
    Publication date: February 15, 2018
    Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt, Daniel Fleischanderl, Gregor Bramberger
  • Patent number: 9650612
    Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: May 16, 2017
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl
  • Patent number: 9458222
    Abstract: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: October 4, 2016
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl, Gregor Bramberger
  • Publication number: 20150056657
    Abstract: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.
    Type: Application
    Filed: September 3, 2014
    Publication date: February 26, 2015
    Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt, Daniel Fleischanderl, Gregor Bramberger
  • Publication number: 20140038264
    Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.
    Type: Application
    Filed: October 10, 2013
    Publication date: February 6, 2014
    Applicants: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl
  • Patent number: 8580554
    Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: November 12, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl
  • Publication number: 20120034674
    Abstract: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.
    Type: Application
    Filed: July 8, 2011
    Publication date: February 9, 2012
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl, Gregor Bramberger
  • Publication number: 20110086411
    Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.
    Type: Application
    Filed: July 30, 2010
    Publication date: April 14, 2011
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl